Table 1.
Results of kinase inhibitor screen using the LATS-BS
| Kinase inhibitor | Target kinase | Increased fold change |
|---|---|---|
| SU 4312 | VEGFR1/2 | 27.88 |
| PD 98059 | MEK | 16.9 |
| BIO | GSKa/b | 14.38 |
| API-2 | PKB | 10.57 |
| Genistein | EGFR | 6.12 |
| Ryuvidine | CDK4 | 5.88 |
| Kinase inhibitor | Target kinase | Suppressed fold change |
|---|---|---|
| Ro 08-2750 | TrkA | 6.51 |
| Ro 31-8220 | General | 5.21 |
| ER 27319 | SYK | 3.71 |
| CGK 733 | ATM/ATR | 1.85 |
| PD 407824 | CHK1 | 1.73 |
| GSK650394 | SGK | 1.73 |
The top kinase inhibitors that activated or inhibited the LATS-BS are shown. The primary target kinases (at 10 μM dose) and fold change in biosensor activity are described for each inhibitor